سعر ايفيجاد 37.5 مجم 28 كبسولة ممتدة المفعول 2024

Effegad 37.5 mg extended-release capsules (28): venlafaxine by Hikma Pharma (Egypt).

• Treatment of major depressive episodes and prevention of recurrence.Population: Adults (UK SmPC)electronic medicines compendium (emc) / MHRA
• Treatment of generalised anxiety disorder, social anxiety disorder, and panic disorder with or without agoraphobia.Population: Adults (UK SmPC)electronic medicines compendium (emc) / MHRA

• Very common: nausea, dry mouth, headache, sweating (including night sweats). Common include dizziness, insomnia, constipation, among others (see UK SmPC).International label, same formulation · electronic medicines compendium (emc) / MHRA

• Hypersensitivity to venlafaxine or excipients. Concomitant irreversible MAOIs; do not start venlafaxine for at least 14 days after stopping an irreversible MAOI; stop venlafaxine at least 7 days before starting an irreversible MAOI.International label, same formulation · electronic medicines compendium (emc) / MHRA

• Suicide risk / clinical worsening: monitor especially early in treatment and after dose changes; higher risk under 25 years in antidepressant meta-analyses.International label, same formulation · electronic medicines compendium (emc) / MHRA
• Serotonin syndrome risk with other serotonergic agents. Dose-related blood pressure increases; screen and monitor BP. QTc prolongation/arrhythmia reported especially in overdose. Avoid abrupt discontinuation — taper.International label, same formulation · electronic medicines compendium (emc) / MHRA
• Not for children/adolescents <18. Sexual dysfunction may occur and can persist after stopping SNRIs.International label, same formulation · electronic medicines compendium (emc) / MHRA

• Irreversible MAOIs / other serotonergic agentsMajorContraindicated with irreversible MAOIs; serotonin syndrome risk with SSRIs/SNRIs, triptans, tramadol, St John’s wort, etc.electronic medicines compendium (emc) / MHRA
• CYP3A4 inhibitors (e.g. ketoconazole)May increase venlafaxine and ODV levels; caution with concomitant CYP3A4 inhibitors.electronic medicines compendium (emc) / MHRA

• Use in pregnancy only if expected benefit outweighs risk; neonatal discontinuation symptoms and possible PPHN/postpartum haemorrhage risk signals with late-pregnancy SSRI/SNRI exposure.International label, same formulation · electronic medicines compendium (emc) / MHRA
• Venlafaxine and ODV excreted in breast milk; risk to infant cannot be excluded.International label, same formulation · electronic medicines compendium (emc) / MHRA

• Venlafaxine: Potent inhibitor of neuronal serotonin and norepinephrine reuptake; weak dopamine reuptake inhibitor.